<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192373</url>
  </required_header>
  <id_info>
    <org_study_id>M20090230</org_study_id>
    <nct_id>NCT01192373</nct_id>
  </id_info>
  <brief_title>Modulation of Free Fatty Acids in Heart Failure Patients With Diabetes: &quot;Effect on Left Ventricular Function&quot;</brief_title>
  <acronym>Metamod3</acronym>
  <official_title>Short Term Modulation of Circulating Free Fatty Acids in Heart Failure Patients With Type 2 Diabetes: &quot;Effect on Myocardial Lipid Content, Left Ventricular Function and Exercise Capacity&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to investigate the the short term effect of low circulating free fatty
      acids in congestive heart failure patients with type 2 diabetes.

      Hypothesis: Low levels of circulating free fatty acids decrease myocardial and peripheral
      muscle lipid content, improves cardiac performance and exercise capacity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>Left ventricular systolic function (Ejection fraction, tissue velocity, Strain and strain rate).
Left ventricular diastolic funtion (E/A ratio, E/e' ratio, IVRT) Cardiac output. All parameters measured at rest and peak exercise and outcome is difference between low and high ciculating free fatty acids.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intracellular lipid content</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>Magnetic Resonans proton spectroscopy (septal myocardial intracellular lipid content) Magnetic Resonans proton spectroscopy (Tibialis anterior muscle intracellular lipid content).
Outcome is difference between low and high ciculating free fatty acids.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise capacity and oxygen consumption</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>Using treadmill and continues oxygen consumption measurement. Outcome is difference between low and high ciculating free fatty acids.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional left ventricular function</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>regional speckle tracking during rest and peak exercise. Outcome is difference between low and high ciculating free fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes hall walk test</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>distance difference between low and high levels of circulating FFA. Outcome is difference between low and high ciculating free fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic and hormonal profile</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>bloodsamples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>High circulating free fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using Heparin af intralipid infusion for 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low circulation free fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>using hyperinsulinaemic euglycemic clamp for 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metabolic substrate modulation</intervention_name>
    <description>for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).</description>
    <arm_group_label>High circulating free fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>metabolic substrate modulation</intervention_name>
    <description>low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.</description>
    <arm_group_label>Low circulation free fatty acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ejection fraction at or lower than 45%

          -  type 2 diabetes

        Exclusion Criteria:

          -  known s-creatinine &gt;220mM

          -  known S-alanine aminotransferase &gt;3 times normal upper limit

          -  other disabilitating conditions

          -  pregnancy

          -  insulin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roni R Nielsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of cardiolgy, Aarhus University hospital, Skejby. Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of cardiology, Aarhus University hospital Skejby,</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

